Versatile coronavirus antibody may be starting point for broader-acting vaccines

Good news! Perhaps finally, we will develop a vaccine against the common cold thanks to SARS-CoV-2!

"... In a new study that appears in Nature Communications, scientists from Scripps Research investigated how the immune system’s previous exposure to cold-causing coronaviruses impact immune response to COVID-19. In doing so, they discovered one cross-reactive coronavirus antibody that’s triggered during a COVID-19 infection.

The findings will help in the pursuit of a vaccine or antibody treatment that works against most or all coronaviruses ...

In later tests, the antibody also neutralized SARS-CoV-1  ...
“We were able to determine that this type of cross-reactive antibody is likely produced by a memory B cell that’s initially exposed to a coronavirus that causes the common cold, and is then recalled during a COVID-19 infection,” ..."

Versatile coronavirus antibody may be starting point for broader-acting vaccines | Scripps Research A special type of antibody is produced in patients who’ve had COVID-19 as well as less-serious coronaviruses that cause colds.

Here is the link to the underlying research article:

Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection (open access)